RxDoctor Payments Data

Raven Deloatch, MD

Internal Medicine · Jackson, NCNPI 1740268598

Payments from drug & device makers

$2,413in general payments, 2019–2025

Across 146 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$343
  • Novartis$296
  • Sanofi-aventis U.S. LLC$225
  • Bayer$219
  • Lilly USA, LLC$217
  • Novo Nordisk$175
  • plus $939 from 16 others

What the payments were for

  • Food & beverage$2,40099%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,413 in reported general payments places this provider in the 80th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$2,537
Medicare patients
111
Services billed
286

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban249$185,395
OzempicSemaglutide158$177,963
JardianceEmpagliflozin88$79,398
FarxigaDapagliflozin Propanediol51$52,016
JanuviaSitagliptin Phosphate47$48,644
XareltoRivaroxaban43$38,734
LinzessLinaclotide47$37,175
TradjentaLinagliptin66$35,248
MounjaroTirzepatide31$34,199
Tresiba Flextouch U-200Insulin Degludec15$30,927
EntrestoSacubitril/Valsartan44$29,731
Tresiba Flextouch U-100Insulin Degludec47$28,477
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$23,158
Lantus SolostarInsulin Glargine,hum.Rec.Anlog126$17,053
InvokanaCanagliflozin23$16,360

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$175$189,842170 claims
PfizerEliquis$141$185,395249 claims
Boehringer IngelheimJardiance, Tradjenta$343$114,645154 claims
AstraZenecaFarxiga, Symbicort$146$66,00091 claims
Johnson & JohnsonXarelto, Invokana$131$55,09466 claims
MerckJanuvia$32$48,64447 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$162$45,36682 claims
AbbVieLinzess, Restasis$46$41,54060 claims
Lilly USA, LLCMounjaro$217$34,19931 claims
NovartisEntresto$296$29,73144 claims
Sanofi-aventis U.S. LLCRenvela$225$5,30616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Jackson

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →